0000914475-24-000011.txt : 20240124
0000914475-24-000011.hdr.sgml : 20240124
20240124174714
ACCESSION NUMBER: 0000914475-24-000011
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240122
FILED AS OF DATE: 20240124
DATE AS OF CHANGE: 20240124
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lippoldt Darin
CENTRAL INDEX KEY: 0001504783
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22705
FILM NUMBER: 24558006
MAIL ADDRESS:
STREET 1: C/O VOLCANO CORPORATION
STREET 2: 3661 VALLEY CENTRE DRIVE, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC
CENTRAL INDEX KEY: 0000914475
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 330525145
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 617-7600
MAIL ADDRESS:
STREET 1: 12780 EL CAMINO REAL
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
wk-form4_1706136421.xml
FORM 4
X0508
4
2024-01-22
0
0000914475
NEUROCRINE BIOSCIENCES INC
NBIX
0001504783
Lippoldt Darin
12780 EL CAMINO REAL
SAN DIEGO
CA
92130
0
1
0
0
Chief Legal Officer
1
Common Stock
2024-01-22
4
M
0
10000
79.02
A
45882
D
Common Stock
2024-01-22
4
S
0
10000
139.8553
D
35882
D
Non-Qualified Stock Option
79.02
2024-01-22
4
M
0
10000
79.02
D
2032-01-31
Common Stock
10000
53372
D
The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 24, 2023. Additionally, Issuer policy
restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $139.80 to $139.99. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on February 28, 2022 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
/s/ Darin Lippoldt
2024-01-24